UnicoCell Biomed Co (TPE:6794) ROCE %: -13.74% (As of Dec. 2025)


TPE:6794 UnicoCell Biomed Co Ltd TPE:6794
83 GF Score
Price NT$85.20
GF Value NT$101.57
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is UnicoCell Biomed Co ROCE %?

UnicoCell Biomed Co TPE:6794 +4.67% 83 ROCE % is -13.74% as of Dec. 2025. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.57 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. UnicoCell Biomed Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -13.74%.

UnicoCell Biomed Co  (TPE:6794) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

UnicoCell Biomed Co ROCE % Related Terms

UnicoCell Biomed Co ROCE % Historical Data

* Premium members only.

The historical data trend for UnicoCell Biomed Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UnicoCell Biomed Co ROCE % Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -26.61 -26.67 -15.50 -12.90 -13.54

UnicoCell Biomed Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.34 -14.04 -15.04 -12.45 -13.74
TPE:6794
83GF Score
UnicoCell Biomed Co Ltd TPE:6794
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UnicoCell Biomed Co ROCE % Calculation

UnicoCell Biomed Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-113.497/( ( (777.889 - 27.13) + (946.012 - 20.728) )/ 2 )
=-113.497/( (750.759+925.284)/ 2 )
=-113.497/838.0215
=-13.54 %

UnicoCell Biomed Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-117.688/( ( (806.138 - 18.535) + (946.012 - 20.728) )/ 2 )
=-117.688/( ( 787.603 + 925.284 )/ 2 )
=-117.688/856.4435
=-13.74 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -13.74% mean?
UnicoCell Biomed Co (TPE:6794) has a ROCE % of -13.74% as of Dec. 2025.
Is UnicoCell Biomed Co's ROCE % too high?
UnicoCell Biomed Co's current ROCE % is -13.74%. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's ROCE % compare to VRTX and REGN?
UnicoCell Biomed Co's ROCE % of -13.74% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. UnicoCell Biomed Co's current ROCE % is -13.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$85.20 — trading 16.1% below its estimated fair value. The current ROCE % is -13.74%. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current ROCE % is -13.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?

Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued. The current stock price of NT$85.20 is trading 16.1% below its estimated GF Value™ of NT$101.57. GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.

Key valuation signals for TPE:6794:

  • ROCE %: -13.74%
  • GF Value™: NT$101.57 vs. price of NT$85.20 (16.1% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UnicoCell Biomed Co Business Description

Address Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score

Get the complete analysis for TPE:6794

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$85.20
Price
NT$101.57
GF Value